Catalyst Pharma Q2 Revenue Up, Acquires FYCOMPA Rights
Ticker: CPRX · Form: 10-Q · Filed: 2024-08-07T00:00:00.000Z
Sentiment: bullish
Topics: revenue-growth, acquisition, pharmaceuticals, 10-Q
TL;DR
CPRX Q2 revenue up to $196.6M, bought FYCOMPA US rights July 11.
AI Summary
Catalyst Pharmaceuticals, Inc. reported its Q2 2024 results, ending June 30, 2024. The company generated $196.6 million in net product revenue for the six months ended June 30, 2024, compared to $174.9 million for the same period in 2023. A significant subsequent event occurred on July 11, 2024, with the acquisition of the U.S. rights for FYCOMPA.
Why It Matters
This filing details Catalyst Pharmaceuticals' financial performance and strategic growth through the acquisition of new product rights, impacting its future revenue streams and market position.
Risk Assessment
Risk Level: medium — The company's reliance on specific products and the inherent risks in pharmaceutical acquisitions and product development contribute to a medium risk level.
Key Numbers
- $196.6M — Net Product Revenue (YTD) (Represents growth compared to the prior year period.)
- $174.9M — Net Product Revenue (Prior YTD) (Provides a basis for year-over-year comparison.)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Filer
- 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL 33134 (address) — Business and Mail Address
- $196.6 million (dollar_amount) — Net product revenue for the six months ended June 30, 2024
- $174.9 million (dollar_amount) — Net product revenue for the six months ended June 30, 2023
- July 11, 2024 (date) — Subsequent event date for FYCOMPA rights acquisition
- FYCOMPA (product) — Acquired U.S. rights
FAQ
What was Catalyst Pharmaceuticals' net product revenue for the six months ended June 30, 2024?
Catalyst Pharmaceuticals reported $196.6 million in net product revenue for the six months ended June 30, 2024.
How does the Q2 2024 net product revenue compare to the same period in 2023?
Net product revenue for the six months ended June 30, 2024, was $196.6 million, an increase from $174.9 million for the same period in 2023.
What significant event occurred on July 11, 2024?
On July 11, 2024, Catalyst Pharmaceuticals acquired the U.S. rights for FYCOMPA.
What is Catalyst Pharmaceuticals' fiscal year end?
Catalyst Pharmaceuticals' fiscal year ends on December 31.
What is the company's primary SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
From the Filing
0000950170-24-092745.txt : 20240807 0000950170-24-092745.hdr.sgml : 20240807 20240807160535 ACCESSION NUMBER: 0000950170-24-092745 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 91 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 241183575 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 10-Q 1 cprx-20240630.htm 10-Q 10-Q false 0001369568 --12-31 Q2 3 5 5 6 years http://fasb.org/us-gaap/2024#LiabilitiesCurrent http://fasb.org/us-gaap/2024#LiabilitiesCurrent 0001369568 us-gaap:MoneyMarketFundsMember 2023-12-31 0001369568 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001369568 cprx:LicensedAndAcquiredIntangiblesForAgamreeMember 2023-12-31 0001369568 cprx:LicenseAgreementForRuzurgiMember 2024-01-01 2024-06-30 0001369568 us-gaap:RetainedEarningsMember 2023-06-30 0001369568 us-gaap:SubsequentEventMember 2024-07-11 0001369568 cprx:LicenseAndOtherRevenueMember 2024-01-01 2024-06-30 0001369568 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001369568 us-gaap:MoneyMarketFundsMember 2024-06-30 0001369568 cprx:ProductRevenueNetMember 2024-01-01 2024-06-30 0001369568 cprx:ProductRevenueNetMember 2023-04-01 2023-06-30 0001369568 cprx:U.s.RightsForFycompaMember 2023-01-01 2023-01-31 0001369568 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001369568 cprx:FycompaMember 2024-04-01 2024-06-30 0001369568 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001369568 cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMember cprx:AgamreeMember srt:MaximumMember 2024-01-01 2024-06-30 0001369568 srt:MaximumMember 2024-01-01 2024-06-30 0001369568 cprx:LicenseAndAssetPurchaseAgreementMember 2022-07-11 2022-07-11 0001369568 cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember cprx:AgamreeMember 2024-01-01 2024-06-30 0001369568 us-gaap:LeaseholdImprovementsMember srt:MinimumMember 2024-06-30 0001369568 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001369568 cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember cprx:AgamreeMember 2024-01-01 2024-06-30 0001369568 cprx:U.s.RightsForFycompaMember srt:MinimumMember cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember us-gaap:RoyaltyAgreementTermsMember 2024-01-01 2024-06-30 0001369568 us-gaap:CollaborativeArrangementMember cprx:DydoPharmaIncMember 2023-01-01 2023-06-30 0001369568 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001369568 cprx:LicenseAndOtherRevenueMember 2024-04-01 2024-06-30 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomersMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001369568 cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember srt:MinimumMember cprx:U.s.RightsForFycompaMember 2024-01-01 2024-06-30 0001369568 cprx:OptionsToPurchaseCommonStockMember 2023-01-01 2023-06-30 0001369568 cprx:RoyaltyLessThanTwoHundredFiftyMillionMember cprx:AgamreeMember 2024-01-01 2024-06-30 0001369568 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0001369568 2023-07-01 2023-07-31 0001369568 us-gaap:CommonStockMember 2024-06-30 0001369568 cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember cprx:U.s.Righ